Education
About Us
Working with TipRanks
Follow Us
PolyPid Ltd. (PYPD)
NASDAQ:PYPD
PYPD Stock Chart & Stats
$4.23
-$0.21(-6.71%)
At close: 4:00 PM EST
$4.23
-$0.21(-6.71%)
Day’s Range― - ―
52-Week Range$2.30 - $5.12
Previous CloseN/A
Volume10.68K
Average Volume (3M)72.46K
Market Cap
$67.25M
Enterprise Value$39.50M
Total Cash (Recent Filing)$12.93M
Total Debt (Recent Filing)$2.80M
Price to Earnings (P/E)―
Beta0.61
Next Earnings
May 13, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding15,897,201
10 Day Avg. Volume44,210
30 Day Avg. Volume72,461
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)6.47
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.21
Forecast
1Y Price Target
$11.67Price Target Upside175.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$850.00K
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe positive recommendation from the DSMB indicates promising efficacy signals for D-PLEX100, enhancing its potential for regulatory approval and commercialization.
Financing And Cash RunwayThe successful financing extends operational runway, providing financial stability to advance clinical trials and regulatory activities.
Market Potential For D-PLEX100The large addressable market for D-PLEX100 in surgical procedures offers significant revenue potential upon successful commercialization and approval.
Bears Say
Consistent Financial LossesOngoing financial losses highlight challenges in achieving profitability, which could impact long-term sustainability and require continued external financing.
Negative EquityNegative equity suggests solvency issues, limiting financial flexibility and increasing reliance on external funding to support operations.
Increased R&D ExpensesRising R&D costs, while necessary for product development, exacerbate financial strain and may delay the path to profitability if not managed effectively.
PolyPid News
PYPD FAQ
What was PolyPid Ltd.’s price range in the past 12 months?
PolyPid Ltd. lowest stock price was $2.30 and its highest was $5.12 in the past 12 months.
What is PolyPid Ltd.’s market cap?
PolyPid Ltd.’s market cap is $67.25M.
When is PolyPid Ltd.’s upcoming earnings report date?
PolyPid Ltd.’s upcoming earnings report date is May 13, 2026 which is in 68 days.
How were PolyPid Ltd.’s earnings last quarter?
PolyPid Ltd. released its earnings results on Feb 11, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.08.
Is PolyPid Ltd. overvalued?
According to Wall Street analysts PolyPid Ltd.’s price is currently Undervalued.
Does PolyPid Ltd. pay dividends?
PolyPid Ltd. does not currently pay dividends.
What is PolyPid Ltd.’s EPS estimate?
PolyPid Ltd.’s EPS estimate is -0.43.
How many shares outstanding does PolyPid Ltd. have?
PolyPid Ltd. has 15,897,201 shares outstanding.
What happened to PolyPid Ltd.’s price movement after its last earnings report?
PolyPid Ltd. reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -1.282%.
Which hedge fund is a major shareholder of PolyPid Ltd.?
Currently, no hedge funds are holding shares in PYPD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PolyPid Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (175.89% Upside)
$11.67 (175.89% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.90%
12-Months-Change
Fundamentals
Return on Equity
-390.53%
Trailing 12-Months
Asset Growth
36.99%
Trailing 12-Months
Company Description
PolyPid Ltd.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
PYPD Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and regulatory momentum: positive Phase III results, clear FDA pre‑NDA agreement, an imminent rolling NDA submission, advanced U.S. partner discussions, and a strategic technology expansion (Kynatrix and GLP‑1 program). These operational highlights position the company for a potential transformative 2026. However, material lowlights include a limited cash runway into H2 2026, rising operating expenses and an increased full‑year net loss, as well as dependence on partnership execution and a likely multi‑month adoption curve post‑approval. Overall the positive regulatory and clinical milestones significantly outweigh the financial and execution risks, but those risks will require near‑term resolution.View all PYPD earnings summariesPYPD Stock 12 Month Forecast
Average Price Target
$11.67
▲(175.89% Upside)
Technical Analysis
Citius Pharmaceuticals
―
SAB Biotherapeutics
―
Liminatus Pharma
―
Tao Synergies
―
Apollomics
―
Ownership Overview
21.60%
Insiders
13.07% Other Institutional Investors
65.33% Public Companies and
Individual Investors